What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
47
GNOM Quote, Financials, Valuation and Earnings
Last price:
$7.48
Seasonality move
:
9.91%
Day range:
$7.66 - $7.81
52-week range:
$6.80 - $11.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
110.1K
Avg. volume:
75.3K
1-year change:
-27.3%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
COPJ
Sprott Junior Copper Miners ETF
|
-- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- |
|
HYDR
Global X Hydrogen ETF
|
-- | -- | -- | -- | -- |
|
NIKL
Sprott Nickel Miners ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
$7.71 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.63 | -- | -- | -- | $0.15 | 0.82% | -- |
|
COPJ
Sprott Junior Copper Miners ETF
|
$20.62 | -- | -- | -- | $2.15 | 10.43% | -- |
|
HEAL
Global X HealthTech ETF
|
$10.78 | -- | -- | -- | $0.00 | 0% | -- |
|
HYDR
Global X Hydrogen ETF
|
$18.55 | -- | -- | -- | $0.09 | 0.49% | -- |
|
NIKL
Sprott Nickel Miners ETF
|
$10.23 | -- | -- | -- | $0.37 | 3.62% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.176 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 0.837 | -- | -- |
|
COPJ
Sprott Junior Copper Miners ETF
|
-- | 0.033 | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | 2.088 | -- | -- |
|
HYDR
Global X Hydrogen ETF
|
-- | 3.234 | -- | -- |
|
NIKL
Sprott Nickel Miners ETF
|
-- | 0.937 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
COPJ
Sprott Junior Copper Miners ETF
|
-- | -- | -- | -- | -- | -- |
|
HEAL
Global X HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
HYDR
Global X Hydrogen ETF
|
-- | -- | -- | -- | -- | -- |
|
NIKL
Sprott Nickel Miners ETF
|
-- | -- | -- | -- | -- | -- |
Global X Genomics & Biotechnology ETF vs. Competitors
-
Which has Higher Returns GNOM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is GNOM or AGNG More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.258, which suggesting that the stock is 25.784% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.536%.
-
Which is a Better Dividend Stock GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.82% to investors and pays a quarterly dividend of $0.15 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or AGNG?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns GNOM or COPJ?
Sprott Junior Copper Miners ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Sprott Junior Copper Miners ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- COPJSprott Junior Copper Miners ETF-- -- -- -
What do Analysts Say About GNOM or COPJ?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Sprott Junior Copper Miners ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Sprott Junior Copper Miners ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Sprott Junior Copper Miners ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 COPJSprott Junior Copper Miners ETF0 0 0 -
Is GNOM or COPJ More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.258, which suggesting that the stock is 25.784% more volatile than S&P 500. In comparison Sprott Junior Copper Miners ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or COPJ?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sprott Junior Copper Miners ETF offers a yield of 10.43% to investors and pays a quarterly dividend of $2.15 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Sprott Junior Copper Miners ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or COPJ?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Sprott Junior Copper Miners ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Sprott Junior Copper Miners ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Sprott Junior Copper Miners ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Sprott Junior Copper Miners ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- COPJSprott Junior Copper Miners ETF-- -- -- --
-
Which has Higher Returns GNOM or HEAL?
Global X HealthTech ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HEALGlobal X HealthTech ETF-- -- -- -
What do Analysts Say About GNOM or HEAL?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X HealthTech ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HEALGlobal X HealthTech ETF0 0 0 -
Is GNOM or HEAL More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.258, which suggesting that the stock is 25.784% more volatile than S&P 500. In comparison Global X HealthTech ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or HEAL?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X HealthTech ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HEAL?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X HealthTech ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X HealthTech ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HEALGlobal X HealthTech ETF-- -- -- --
-
Which has Higher Returns GNOM or HYDR?
Global X Hydrogen ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Hydrogen ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HYDRGlobal X Hydrogen ETF-- -- -- -
What do Analysts Say About GNOM or HYDR?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Hydrogen ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Hydrogen ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Hydrogen ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HYDRGlobal X Hydrogen ETF0 0 0 -
Is GNOM or HYDR More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.258, which suggesting that the stock is 25.784% more volatile than S&P 500. In comparison Global X Hydrogen ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or HYDR?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Hydrogen ETF offers a yield of 0.49% to investors and pays a quarterly dividend of $0.09 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Hydrogen ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HYDR?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Hydrogen ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Hydrogen ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Hydrogen ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Hydrogen ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HYDRGlobal X Hydrogen ETF-- -- -- --
-
Which has Higher Returns GNOM or NIKL?
Sprott Nickel Miners ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Sprott Nickel Miners ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- NIKLSprott Nickel Miners ETF-- -- -- -
What do Analysts Say About GNOM or NIKL?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Sprott Nickel Miners ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Sprott Nickel Miners ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Sprott Nickel Miners ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 NIKLSprott Nickel Miners ETF0 0 0 -
Is GNOM or NIKL More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.258, which suggesting that the stock is 25.784% more volatile than S&P 500. In comparison Sprott Nickel Miners ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or NIKL?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sprott Nickel Miners ETF offers a yield of 3.62% to investors and pays a quarterly dividend of $0.37 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Sprott Nickel Miners ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or NIKL?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Sprott Nickel Miners ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Sprott Nickel Miners ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Sprott Nickel Miners ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Sprott Nickel Miners ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- NIKLSprott Nickel Miners ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is up 13.72% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 4.5% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 0.87% over the past day.
